Patent · US Active

Fructosylated puerarin, and preparation method and use thereof

US8598128B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Inventors

Bingfang He · Nanjing, CN
Xueming Wu · 安丰镇, CN
Jianlin Chu · 安丰镇, CN
Bin Wu · Sharon, US
Sen Zhang · 安丰镇, CN
Pingkai Ouyang · Nanjing, CN

Key dates

Filing date	Sep 23, 2011
Grant date	Dec 3, 2013
Priority date	—
Expiry date	Sep 23, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12P19/605
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.